Mebias Discovery, Inc
Biotechnology Research • 
Philadelphia, Pennsylvania, United States • 1-10 Employees
Company overview
| Headquarters | 3001 Market Street, Suite 140, Philadelphia, PA 19104, US |
| Phone number | +12672180854 |
| Website | |
| NAICS | 541714 |
| SIC | 873 |
| Keywords | Conformation Based Sar, Gpcr Drug Discovery, Protein Nmr |
| Founded | 2015 |
| Employees | 1-10 |
| Socials |
Key Contact at Mebias Discovery, Inc
Brett Tounge
Co-Founder
Mebias Discovery, Inc Email Formats
Mebias Discovery, Inc uses 1 email format. The most common is {first initial}.{last name} (e.g., j.doe@mebiasdiscovery.com), used 100% of the time.
| Format | Example | Percentage |
|---|---|---|
{first initial}.{last name} | j.doe@mebiasdiscovery.com | 100% |
About Mebias Discovery, Inc
MEBIAS holds a game-changing platform to discover next generation, GPCR drugs devoid of on-target side effects. G-protein Coupled Receptor (GPCR) therapeutics comprise ~30% of current prescribed drugs. Mebias’ understanding of protein dynamics of GPCRs offers a unique advantage. Given our experience and access to two key technologies – native GPCR purification and protein nuclear magnetic resonance – our approach offers resolution to identify agonists that is lacking in other methodologies. We have delivered a series of biased mu opioid receptor scaffolds among which is an clinical stage compound. The Mebias platform significantly decreases the time and costs to deliver optimized leads. Our initial areas of focus are CNS/Pain, OUD, Metabolic, and Inflammatory related disorders. Expertise / Assets • Rapid identification and optimization of IND candidates devoid of on-target adverse effects, enabled by a fully validated assay suite which identifies ligand-induced dynamic conformation of GPCR signaling. • Differentiated mu-opioid receptor agonist (MEB-1170) for the treatment of OUD and pain (lacking respiratory depression/GI motility issues/tolerance and does not demonstrate potential for abuse liability) Business Proposal • Seeking co-development and/or license our mu-opioid drug candidates • Research funding/collaboration for lead discovery of additional targets in selected disease areas
Mebias Discovery, Inc revenue & valuation
| Annual revenue | $5,000,000 |
| Revenue per employee | $1,250,000 |
| Estimated valuation?This valuation is estimated based on industry average for the Biotechnology Research industry and current estimated revenues | $16,000,000 |
| Total funding | $630,700 |
Employees by Management Level
Total employees: 1-10
Seniority
Employees
Employees by Department
Mebias Discovery, Inc has 1 employees across 1 departments.
Departments
Number of employees
Mebias Discovery, Inc Tech Stack
Discover the technologies and tools that power Mebias Discovery, Inc's digital infrastructure, from frameworks to analytics platforms.
JavaScript libraries
Web servers
Form builders
Miscellaneous
Miscellaneous
Programming languages
Blogs
JavaScript libraries
Page builders
JavaScript libraries
Databases
Netherlands
Canada
Frequently asked questions
4.8
40,000 users
